Impact of the CETA on the costs of patented drugs

A new CCPA report, by Dr. Joel Lexchin and Marc-André Gagnon, examines the impact of the Comprehensive and Economic Trade Agreement (CETA) on pharmaceuticals. The authors find that the tentative EU-Canada trade deal will further tilt the balance towards the protection of brand-name drug manufacturers and their profits and away from Canadian consumers—resulting in significantly higher drug costs for Canadians. The study also examines the latest revelations about the tentative trade agreement, and asserts that the CETA will seriously impact the ability of Canadians to afford quality health care.

Read more in the report, CETA and Pharmaceuticals: Impact of the trade agreement between Europe and Canada on the costs of patented drugs.